 |
The Journal of Neuroscience, August 3, 2005, 25(31):7101-7110; doi:10.1523/JNEUROSCI.5258-04.2005
Previous Article | Next Article 
Neurobiology of Disease
Inhibition of Cystine Uptake Disrupts the Growth of Primary Brain Tumors
Wook Joon Chung,1
Susan A. Lyons,1
Gina M. Nelson,1
Hashir Hamza,1
Candece L. Gladson,2
G. Yancey Gillespie,3 and
Harald Sontheimer1
1Department of Neurobiology and Civitan International Research Center, and Departments of 2Pathology and 3Neurosurgery, The University of Alabama at Birmingham, Birmingham, Alabama 35294-0021
Glial cells play an important role in sequestering neuronally released glutamate via Na+-dependent transporters. Surprisingly, these transporters are not operational in glial-derived tumors (gliomas). Instead, gliomas release glutamate, causing excitotoxic death of neurons in the vicinity of the tumor. We now show that glutamate release from glioma cells is an obligatory by-product of cellular cystine uptake via system , an electroneutral cystine-glutamate exchanger. Cystine is an essential precursor for the biosynthesis of glutathione, a major redox regulatory molecule that protects cells from endogenously produced reactive oxygen species (ROS). Glioma cells, but not neurons or astrocytes, rely primarily on cystine uptake via system for their glutathione synthesis. Inhibition of system causes a rapid depletion of glutathione, and the resulting loss of ROS defense causes caspase-mediated apoptosis. Glioma cells can be rescued if glutathione status is experimentally restored or if glutathione is substituted by alternate cellular antioxidants, confirming that ROS are indeed mediators of cell death. We describe two potent drugs that permit pharmacological inhibition of system . One of these drugs, sulfasalazine, is clinically used to treat inflammatory bowel disease and rheumatoid arthritis. Sulfasalazine was able to reduce glutathione levels in tumor tissue and slow tumor growth in vivo in a commonly used intracranial xenograft animal model for human gliomas when administered by intraperitoneal injection. These data suggest that inhibition of cystine uptake into glioma cells through the pharmacological inhibition of system may be a viable therapeutic strategy with a Food and Drug Administration-approved drug already in hand.
Key words: excitotoxicity; glutathione; glutamate transport; glial progenitor cells; sulfasalazine; (S)-4-carboxyphenylglycine
Received Dec 23, 2004;
revised June 17, 2005;
accepted June 17, 2005.
This article has been cited by other articles:

|
 |

|
 |
 
S. A. Grossman, X. Ye, M. Chamberlain, T. Mikkelsen, T. Batchelor, S. Desideri, S. Piantadosi, J. Fisher, and H. A. Fine
Talampanel With Standard Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma: A Multicenter Phase II Trial
J. Clin. Oncol.,
September 1, 2009;
27(25):
4155 - 4161.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. K. Mantena, M. K. Unnikrishnan, and P. Uma Devi
Radioprotective effect of sulfasalazine on mouse bone marrow chromosomes
Mutagenesis,
July 1, 2008;
23(4):
285 - 292.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. E. Featherstone and S. A. Shippy
Regulation of Synaptic Transmission by Ambient Extracellular Glutamate
Neuroscientist,
April 1, 2008;
14(2):
171 - 181.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Lyons, W. J. Chung, A. K. Weaver, T. Ogunrinu, and H. Sontheimer
Autocrine Glutamate Signaling Promotes Glioma Cell Invasion
Cancer Res.,
October 1, 2007;
67(19):
9463 - 9471.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Fogal, J. Li, D. Lobner, L. D. McCullough, and S. J. Hewett
System xc Activity and Astrocytes Are Necessary for Interleukin-1{beta}-Mediated Hypoxic Neuronal Injury
J. Neurosci.,
September 19, 2007;
27(38):
10094 - 10105.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Augustin, Y. Grosjean, K. Chen, Q. Sheng, and D. E. Featherstone
Nonvesicular Release of Glutamate by Glial xCT Transporters Suppresses Glutamate Receptor Clustering In Vivo
J. Neurosci.,
January 3, 2007;
27(1):
111 - 123.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Y. Shih, H. Erb, X. Sun, S. Toda, P. W. Kalivas, and T. H. Murphy
Cystine/Glutamate Exchange Modulates Glutathione Supply for Neuroprotection from Oxidative Stress and Cell Proliferation
J. Neurosci.,
October 11, 2006;
26(41):
10514 - 10523.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T.-Y. Kim, S. Zhong, C. R. Fields, J. H. Kim, and K. D. Robertson
Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma.
Cancer Res.,
August 1, 2006;
66(15):
7490 - 7501.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Sun, A. Y. Shih, H. C. Johannssen, H. Erb, P. Li, and T. H. Murphy
Two-photon Imaging of Glutathione Levels in Intact Brain Indicates Enhanced Redox Buffering in Developing Neurons and Cells at the Cerebrospinal Fluid and Blood-Brain Interface
J. Biol. Chem.,
June 23, 2006;
281(25):
17420 - 17431.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|